Dartmouth-Hitchcock logo
Back
 
AXL Enduring Material - Toxicology Testing and Risk Stratification Considerations

This series is designed to increase treatment capacity for opioid use disorders by training more prescribers to be able to treat substance or opioid use disorders.
Content Includes:

  • Principles of patient risk stratification for drug test frequency
  • Impact of COVID 19 on risk assessment
  • Use of confirmatory testing
  • Drug test randomization strategies
  • Vermont OBOT Stability Index tool
  • Impact of MAT regulatory changes during the State of Emergency

Activity Details

Start Date:  September 1, 2021
End Date:  September 1, 2024


You may claim CME or CNE credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Register for the learning activity by creating an account or logging in to your account.
  2. Click Continue to navigate to the Evaluation tab; then click the Launch button to start the evaluation.
  3. Complete and Submit the evaluation and attestation form.

When the evaluation is submitted, you will be awarded credit. You may access your transcript for verification of participation at any time via Your Account. Need help? Visit the Support Page, send an Email, or call the Center for Learning and Professional Development at (603) 653-1234, Option 1.

Registration

There is no fee for this activity, but to receive credit(s) you must register online and complete the online evaluation (you must register to access this form).

Speaker
  • Tony Folland serves as the Clinical Services Manager and State Opioid Treatment Authority for the Vermont Department of Health, Division of Alcohol and Drug Abuse Programs and has been in State service since 2010. In the Vermont system of care, Tony has regulatory oversight of both the Hub (OTP) providers and DATA 2000 waivered prescribers. Prior to state government, he previously served for nearly 20 years as a clinician, program director and clinical director in various MH/SA organizations, both in rural and urban settings, and was both a Clinician and, subsequently, Clinical Director of Vermont’s initial Buprenorphine Induction Hub for several years. With regard to the current iteration of the Hub and Spoke System, Tony was honored to Chair the Medical provider development subcommittee, participating in the clinical assessment subcommittee and serving on the Clinical & Scientific Leadership Committee to develop the provider Learning Collaborative to support prescriber education and practice improvement.
Learning Outcome(s)

At the conclusion of this learning collaborative, (at least 75% of) participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.

Accreditation

Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Dartmouth-Hitchcock Nursing Continuing Education Council is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity carries 1.0 contact hour.

Requirements for Successful Completion

In order to receive credit for this Continuing Medical Education, Continuing Nursing Education (CME/CNE) activity, you must:

  • Complete the entire module
  • fill out the activity evaluation. (you must register to access).
Disclosure

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have reported NO financial interest or relationship* with various companies. There were no individuals in a position to control the content that refused to disclose.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Bibliographic Resources

For questions email the presenter:
Anthony Folland
Anthony.Folland@vermont.gov

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center
clpd.support@hitchcock.org


Type:     Internet Activity (Enduring Material)
9 Registered Users

0